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TREATMENT OF PEMPHIGUS VULGARIS AND PEMPHIGUS FOLIACEUS:
EXPERIENCE WITH 71 PATIENTS OVER A 20 YEAR PERIOD*
Nurimar C. FERNANDES(1) & Mauricio PEREZ(2)
SUMMARY
Forty one cases of pemphigus vulgaris and thirty cases of pemphigus foliaceus were investigated at Hospital Universitário Clementino
Fraga Filho from 1978 to 1999. They were divided into two treatment groups: one group received up to 100 mg of oral prednisone
daily and the other group received >120 mg daily. The dose up to 100 mg provided good initial control of pemphigus vulgaris and
pemphigus foliaceus and did not increase the mortality rate associated to disease. The dose >120 mg induced higher morbidity. These
data allowed us to establish a regimen of oral prednisone (1–2 mg/kg/daily) with maximum of 120 mg daily in the treatment of
pemphigus vulgaris and pemphigus foliaceus.
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INTRODUCTION
Systemic corticosteroids are the most useful drugs for the treatment
of pemphigus6. Some patients have mild disease manifested by only a few
indolent lesions that can be controlled simply with low doses of
corticosteroids. Others have fulminating disease that cannot be controlled
even with massive doses. Efforts are rarely made to correlate therapeutic
results with extent or activity of disease even though the severe cases
require larger doses of corticosteroids and have a higher mortality. The
terms activity, extent and severity are poorly defined; as a consequence,
the evaluation of therapeutic results in published studies must be limited
to an analysis of two basic variables: mortality and remission. The
methodology used to define and study adverse effects is so wide and poorly
described in most studies that no attempt have been made to analyze it1,4,6.
We present a retrospective study of the clinical course of pemphigus
vulgaris and pemphigus foliaceus treated with prednisone.
MATERIAL AND METHODS
41 cases of pemphigus vulgaris and 30 cases of pemphigus foliaceus
were investigated at Hospital Universitário Clementino Fraga Filho, Rio
de Janeiro, from 1978 to 199912 with the following criteria:
1. histological confirmation; the direct immunofluorescence was
performed only in case of doubtful diagnosis; the indirect
immunofluorescence test is not routinely performed in the follow up
of pemphigus cases4.
2. therapy initiated with oral prednisone: a) 2mg/kg/daily in the
extensive pemphigus vulgaris that is with involvement of the mucous
membranes and skin9 or rapidly progressive skin disease; b) 2mg/
kg/daily in the extensive pemphigus foliaceus that is rapidly
progressive skin disease; c) 1 mg/kg/daily in pemphigus vulgaris
when oral lesions were the only clinical manifestations; d) 1 mg/kg/
daily in not extensive and progressive skin disease of pemphigus
foliaceus8; e) 1mg/kg/daily for both pemphigus in the presence of
relative contraindications to corticosteroids: peptic ulcer, diabetes,
cataracts, osteoporosis, hypertension, tuberculosis, obesity,
glaucoma, old age.
3. both groups were kept on prednisone for 4–6 weeks to achieve a
state in which no new lesions were appearing and old lesions were
healing (control phase); then it was gradually tapered (10 mg every
ten days interval) until 20 mg daily was reached. From this stage on,
the following schedule was employed: 20 mg ( 6 months); 10 mg (6
months); 5 mg (6 months); 2.5 mg (6 months). The drug could be
stopped when a state of no new lesions were observed in the last
twelve months.
4. the 20 cases submitted to a combined treatment schedule with
azathioprine (pemphigus vulgaris), dapsone (pemphigus vulgaris)
or chloroquine (pemphigus foliaceus) were not included in the present
study; these situations were the following:
• Patients who were not controlled to initial therapy with
prednisone until 10 weeks4;
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• Patients being treated with prednisone in whom complications
developed with its use (psychosis, aseptic necrosis of femur,
emotional lability, severe hypertension, uncontrolled diabetes)4;
• Patients in whom repeated attempts to taper corticosteroids was
associated with recurrence of disease4.
5. in a 5-year-follow-up, all cases of pemphigus (vulgaris and foliaceus)
were assessed on clinical development of prednisone side effects:
infections (impetigo, septicemia, kidney infection, candidiasis, tinea,
herpes simplex, zoster, molluscum), hypertension, diabetes,
psychosis, Cushing syndrome, cataracts, aseptic necrosis of femur
and peptic ulcer. The mortality rates were evaluated in pemphigus
vulgaris and foliaceus (each one) considering that this variable
depends also on the disease itself.
6. Chi-square (Yates) or Fisher exact test were used whenever
appropriate.
RESULTS
Twenty-eight females and 13 males aged 20 to 80 years had
pemphigus vulgaris (Table 1). The initial dose did not influence the
response to treatment (p>0.05) (Table 2) and mortality rate (p>0.05)
(Table 3) in these cases.
Nineteen males and eleven females aged 10 to 80 years had
pemphigus foliaceus (Table 1). The initial dose did not influence the
response to treatment (p>0.05) (Table 4) and mortality rate (p>0.05)
(Table 5) in these cases. The side effects could be related to larger doses
of prednisone (p<0.05) (Table 6) in both diseases.
DISCUSSION
In our retrospective study we grouped the patients according to the
initial dose of prednisone as other investigators7,9; the dose was
determined by criteria of extension of skin disease (pemphigus vulgaris
and pemphigus foliaceus) and mucous disease (pemphigus vulgaris).
The dose higher than 120 mg daily was not more effective in the initial
control of pemphigus vulgaris (p>0.05) [Table 2] and pemphigus
foliaceus (p>0.05) [Table 4]. The dosage up to 100 mg daily provided
good initial response in both pemphigus (control phase).
Table 5
Distribution of cases (pemphigus foliaceus) according to mortality
Mortality
Dose Yes No Total
80 – 100 2(9%) 20 22
> 120 1(12%) 7 8
Total 3 27 30
HUCFF-UFRJ (1978-1999); p>0.05
Table 2
Distribution of cases (Pemphigus vulgaris), according to dosage of prednisone
and response to treatment
Response
Dose Yes No Total
80 – 100 9 3 12
> 120 21 8 29
Total 30 11 41
HUCFF-UFRJ (1978-1999); p>0.05
Table 1
Distribution of cases according to age and sex
PV PF
sex sex
Age Male Female Male Female Total
10 – 19 - - 1 1 2
20 – 29 2 2 - 2 6
30 – 39 2 8 6 2 18
40 – 49 4 2 3 1 10
50 – 59 3 4 2 1 10
60 – 69 1 6 5 2 14
70 – 80 1 6 2 2 11
Total 13 28 19 11 71
HUCFF-UFRJ (1978-1999); PV – Pemphigus vulgaris; PF – Pemphigus foliaceus
Table 4
Distribution of cases (Pemphigus foliaceus), according to dosage of
prednisone and response to treatment
Response
Dose Yes No Total
80 – 100 15 7 22
> 120 6 2 8
Total 21 9 30
HUCFF-UFRJ (1978-1999); p>0.05
Table 3
Distribution of cases (pemphigus vulgaris) according to mortality
Mortality
Dose Yes No Total
80 – 100 0 12 12
> 120 3 (10%) 26 29
Total 3 38 41
HUCFF-UFRJ (1978-1999); p>0.05
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There is no consensus regarding the initial dosage needed to induce
remission in pemphigus vulgaris. Some consider that it should be 200
mg daily or even more6,7 because this is life – saving and contributes to
long term remission. Other consider that a daily oral prednisone dose of
180 mg is an important cause of treatment related fatality2. Many patients
are treated with daily steroid doses of 40 – 80 mg8,12. A lack of prospective
studies and of well controlled trials contribute to the dilemma over the
best initial dose and maintenance theraphy1,3.
For pemphigus foliaceus, the Brazilian authors state oral prednisone
(1 – 1.5 mg/kg/daily)8 or oral triamcinolone (48 mg/daily)11. It is quite
impossible to compare our figures because several data are lacking in
these papers10,11.
In our sample the mortality rate could not be related to the initial
maximum dose of prednisone required to induce control in the cases of
pemphigus vulgaris (p>0.05) (Table 3) and pemphigus foliaceus (p>0.05)
(Table 5).
The literature contains contradictory reports about the relationship
between the initial-dose of prednisone and mortality as well as the effect
of initial dosage on the subsequent course of pemphigus vulgaris and
foliaceus. These discrepancies are, in part, due to differences in data
presentation.
The mortality rates in our cases are in accordance with literature
data both for pemphigus vulgaris11 (10%) (Table 3) and pemphigus
foliaceus5,10,11 (9% to 12%) (Table 5). Prior to the use of glucocorticoid
therapy, significant mortality was associated with patients having
pemphigus; most of the deaths used to occur during the first 2–3 months
of therapy7. Today it is due to drug associated complications12.
In our sample increased morbidity was associated with statistical
significance to >120 mg prednisone (p<0.05) (Table 6). As the mentioned
side effects are complications of therapy, we analyzed both pemphigus
together. The infections, hypertension and diabetes were the most frequent
complications and could be (one or more) present in the same patient.
The two cases of psychosis2 and one case of aseptic necrosis of femur
were not switched to adjuvant therapy (azathioprine, chloroquine,
dapsone) for contraindications (renal impairment, retinopathy and glucose
6 – phosphate dehydrogenase deficiency).
Several authors believe that doses over 120 mg or 180 mg greatly
increase treatment related morbidity2,12. It seems that it is not merely a
high daily dose but the duration for which it is given that is important2,6.
Mortality, morbidity and the length of clinical remission remain for
some authors12 the best measures of the efficacy of a therapeutic regimen.
We decided not to evaluate the lenght of clinical remission because the
patient’s compliance intervenes with relapse rates.
It is probable that immediate high dose treatment in every case of
pemphigus does not seem absolutely essential anymore14. It seems to be
possible to try a mild therapy in patients with only a few lesions and
slow progression14.
CONCLUSIONS
Our retrospective study indicates that an initial dose up to 100 mg
daily of prednisone during 4–6 weeks provides good initial control of
pemphigus vulgaris and pemphigus foliaceus; this dosage, besides, does
not increase mortality rate associated to disease. On the other hand, higher
doses than 120 mg are related to increased morbidity. These results
allowed us to establish a regimen of oral prednisone (1–2 mg/kg/daily)
with maximum of 120 mg daily in the treatment of pemphigus vulgaris
and pemphigus foliaceus.
RESUMO
Tratamento do pênfigo vulgar e pênfigo foliáceo: experiência com
71 pacientes no período de 20 anos
Quarenta e um casos de pênfigo vulgar e trinta casos de pênfigo
foliáceo foram investigados no Hospital Universitário Clementino Fraga
Filho, no período 1978–1999. Os pacientes foram divididos em dois
grupos de tratamento: um recebendo até 100 mg/dia de prednisona e o
outro grupo >120 mg diariamente. Com o primeiro esquema, houve bom
controle inicial dos pênfigos sem aumento da taxa de mortalidade
associada às doenças. A dose acima de 120 mg induziu maior morbidade.
Os resultados permitiram estabelecer um esquema de prednisona (1–2
mg/kg/dia) com dose máxima de 120 mg diários no tratamento dos
pênfigos vulgar e foliáceo.
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Table 6
Distribution of cases according to dosage of prednisone and side effects
Dose  Infections  Hyper- Diabetes  Cushing  Psy-  Cata- Aseptic  Peptic  Total
tension syndrome chosis racts necrosis ulcer
of femur
80-100 16 5 6 2 - - 1 1 31
> 120 48 7 4 3 2 2 - - 66
Toal 64 12 10 5 2 2 1 1 97
HUCFF-UFRJ (1978-1999); p<0.05
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